Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 13/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 8/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207853 | 0.89 | CDC7 (0.50) | ALDH1A1GAACDC7RPS6KA3PARP1 | |
| SCHEMBL31207898 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL2954628 | 0.71 | MEN1 (0.31) | — | |
| SCHEMBL14251266 | 0.70 | ALDH1A1 (0.50) | ALDH1A1GAACDC7RPS6KA3RPS6KA2 | |
| SCHEMBL31460144 | 0.70 | CDC7 (0.48) | ALDH1A1GAACDC7RPS6KA3RPS6KA2 | |
| SCHEMBL5000027 | 0.69 | CDC7 (0.83) | CDC7RPS6KA3RPS6KA2 | |
| SCHEMBL15332872 | 0.68 | CDC7 (0.46) | ALDH1A1GAACDC7RPS6KA3RPS6KA2 | |
| SCHEMBL2555160 | 0.68 | KDM4E (0.48) | ALDH1A1CDC7RPS6KA3RPS6KA2PARP1 | |
| SCHEMBL19253533 | 0.68 | GABRG2 (0.31) | — | |
| SCHEMBL25433466 | 0.67 | CDC7 (0.51) | CDC7RPS6KA3RPS6KA2PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | claimed |
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | ALDH1A1 771/4885GAA 1057/4885CDC7 4012/4885 |
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | ALDH1A1 713/4885GAA 951/4885CDC7 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.